Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective oestrogen receptor modulator (SERM)

Ospemifene

Brand names: Senshio

Ospemifene is an oral selective oestrogen receptor modulator (SERM) used to treat moderate to severe symptomatic vulvovaginal atrophy in postmenopausal women not suitable for local vaginal oestrogen.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It acts as an oestrogen receptor agonist on vaginal and vulvar tissue, improving epithelial maturation and reducing dyspareunia, while exerting mixed agonist-antagonist effects elsewhere.

Prescribing in practice

  • It is contraindicated in women with active or past venous thromboembolism and in undiagnosed vaginal bleeding, and carries a thromboembolic and endometrial risk like other agents with oestrogenic activity.
  • It should not be used alongside oestrogens or other oestrogen receptor agonist/antagonists.
  • It is contraindicated in known, suspected, or history of breast cancer.

Monitoring

No routine blood monitoring is required, but investigate any unexpected vaginal bleeding and review thromboembolic risk periodically.

Counselling the patient

  • Take the tablet once daily with food.
  • Report any unexpected vaginal bleeding, or leg pain, swelling, breathlessness, or chest pain promptly.
  • Hot flushes are a recognised side effect.

Evidence & guidelines

Licensed for postmenopausal vulvovaginal atrophy on the basis of randomised controlled trials, as reflected in the SPC.

Reference: NICE TA876; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways